Bangladesh Medical Device Definition: Six Intended Purposes

1. Key takeaways

Bangladesh places the definition of a medical device directly in the Drug and Cosmetics Act, 2023 (Act No. 29 of 2023, in force 2023-09-18). The definition has two limbs. Limb (a) lists the physical forms a device may take and then sets out six intended purposes, numbered (i) to (vi). Limb (b) is an open interface: any device or diagnostic reagent declared by the government by notification in the official Gazette is a device as well. The definition expressly covers diagnostic reagents in three categories, namely in vitro, in vivo and in silico, and it expressly covers software. Its scope of application is written as being for use in human beings or animals.

• Two-limb structure: an enumerated list of forms plus a standing gazette power.
• Six intended purposes decide whether a product is in scope, and meeting any one of them is enough to bring it inside the definition.
• Three reagent categories are named, so computational diagnostics are covered on the face of the statute.
• Software appears in the list of device forms, with no carve-out attached.
• Animal use is inside the definition, which brings veterinary devices into the same route.

2. Legal basis

The provision is short but structurally important, because every later question about classification, documentation and route depends on whether the product falls inside it. The table reproduces the elements that a scope assessment has to address, purpose by purpose.

3. Expert insights

Insight one: the three Latin terms sit side by side, and that is the forward-looking part of the drafting. Most markets write in vitro diagnostics into the definition and stop there. Bangladesh names in vivo reagents and in silico, that is computer-simulated, diagnostic reagents in the same breath, covering three reagent categories in one clause. The consequence is practical rather than academic. A diagnostic product built on an algorithm or a model cannot argue exemption in Bangladesh on the ground that it is software rather than a reagent, because the reagent limb already reaches computational diagnostics.

Insight two: software is inside the statute, and SaMD has no separate channel. Software is listed among the device forms, so software as a medical device follows exactly the same classification and registration route as hardware. There is no software exemption and no low-risk software waiver. Practitioners arriving from jurisdictions where standalone software enjoys a lighter path should expect the full file, including the quality management evidence that attaches to the assigned class.

Insight three: limb (b) is a permanently open door. Wherever the government declares a product by notification in the official Gazette, that product enters the definition whether or not it matches the enumerated forms or the six purposes. The final interpretive authority over the product boundary therefore does not rest with the manufacturer. A company cannot close the question by showing that none of the six purposes applies, because the gazette route remains available to the authority. The correct posture is to seek written confirmation instead of issuing a self-certified negative finding.

Insight four: veterinary devices remain with the DGDA. The definition states human beings or animals, so veterinary devices and animal diagnostic reagents travel the same registration route. This point is rarely mentioned in Chinese-language material yet it directly changes the compliance assessment for exporters of veterinary equipment. A product that would be outside the device regime in another market may be squarely inside it here, and the file, the class and the local representative obligations follow accordingly.

4. Practical recommendations

• Begin the scope assessment by reading the instructions for use against (a)(i) to (vi), purpose by purpose, and record the result for each one rather than recording a single overall conclusion.
• Where any purpose is met, treat the product as a device and proceed to classification without further debate. Argument spent on scope at that point is argument not spent on the class question, and the class is what determines the evidence that will be required.
• Where none of the six is met, do not issue a non-device conclusion. Recommend written confirmation from the DGDA, because the gazette power in limb (b) is always available.
• For products containing an algorithm module, describe in the technical documentation where the algorithm acts and what form of information it outputs, so that the file does not have to be rebuilt after an in silico reagent finding.
• For veterinary products, apply the same route as for human products and do not assume a lighter pathway exists.

5. Verification checklist

• □ All six intended purposes (i) to (vi) checked individually against the instructions for use
• □ For products containing diagnostic reagents, the in vitro, in vivo or in silico category has been identified
• □ Products containing software modules are handled as devices, with no claim of software exemption
• □ Veterinary products are treated as devices on the same route as human products
• □ Products meeting none of the six purposes are listed as items requiring written confirmation from the DGDA

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com